<SEC-DOCUMENT>0001606498-20-000022.txt : 20200416
<SEC-HEADER>0001606498-20-000022.hdr.sgml : 20200416
<ACCEPTANCE-DATETIME>20200416161332
ACCESSION NUMBER:		0001606498-20-000022
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20200416
DATE AS OF CHANGE:		20200416
EFFECTIVENESS DATE:		20200416

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Avanos Medical, Inc.
		CENTRAL INDEX KEY:			0001606498
		STANDARD INDUSTRIAL CLASSIFICATION:	ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
		IRS NUMBER:				464987888
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36440
		FILM NUMBER:		20796554

	BUSINESS ADDRESS:	
		STREET 1:		5405 WINDWARD PARKWAY
		CITY:			ALPHARETTA
		STATE:			GA
		ZIP:			30004
		BUSINESS PHONE:		678-425-9273

	MAIL ADDRESS:	
		STREET 1:		5405 WINDWARD PARKWAY
		CITY:			ALPHARETTA
		STATE:			GA
		ZIP:			30004

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Halyard Health, Inc.
		DATE OF NAME CHANGE:	20140424
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>a2020avnsdefa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ib3ee2179de47442eb9515f719b5d9f52_29"></div><div style="height:45pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%;">UNITED STATES</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Washington, D.C. 20549</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%;">SCHEDULE 14A</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Proxy Statement Pursuant to Section 14(a) of the Securities Exchange</font></div><div style="text-align:center;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;"> Act of 1934 (Amendment No.)</font></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:48.000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:48.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#254;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> Filed by the Registran</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#168;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> Filed by a Party other than the Registran</font></div></td></tr></table></div><div><font><br></font></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:4.752%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:91.248%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Check the appropriate box&#58;</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#168;</font></div><div style="text-align:center;"><font><br></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Preliminary Proxy Statement</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#168;</font></div><div style="text-align:center;"><font><br></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14a-6(e)(2))</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#168;</font></div><div style="text-align:center;"><font><br></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Definitive Proxy Statement</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">x</font></div><div style="text-align:center;"><font><br></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Definitive Additional Materials</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#168;</font></div><div style="text-align:center;"><font><br></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Soliciting Material Under Rule 14a-12</font></td></tr></table></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%;">Avanos Medical, Inc.</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">(Name of Registrant as Specified in its Charter)</font></div><div style="text-align:center;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">(Name of Person(s) Filing Proxy Statement, if Other than the Registrant)</font></div><div style="text-align:center;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:4.752%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:91.248%;"></td><td style="width:1.0%;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payment of Filing Fee (Check the appropriate box)&#58;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#254;</font></div><div style="text-align:center;"><font><br></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">No fee required.</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" rowspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#168;</font></div><div style="text-align:center;"><font><br></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1) Title of each class of securities to which transaction applies&#58;</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2) Aggregate number of securities to which transaction applies&#58;</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3) Per unit price or other underlying value of transactions computed pursuant to Exchange Act Rule 01-11&#58;</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4) Proposed maximum aggregate value of transaction.</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5) Total fee paid&#58;</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#168;</font></div><div style="text-align:center;"><font><br></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fee paid with preliminary materials.</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#168;</font></div><div style="text-align:center;"><font><br></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Check box if any part of the fee is offset as provided by Exchange Act Rule 01-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, of the Form or Schedule and the date of its filing.</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1) Amount Previously Paid&#58;</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2) Form, Schedule or Registration Statement No.&#58;</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3) Filing Party&#58;</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4) Date Filed&#58;</font></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div id="ib3ee2179de47442eb9515f719b5d9f52_48"></div><div style="height:45pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.132%;"><tr><td style="width:1.0%;"></td><td style="width:28.453%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:37.092%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:28.455%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:65pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:65pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><img alt="avanoslogo1.jpg" src="avanoslogo1.jpg" style="height:35px;width:215px;"></div></td><td colspan="3" style="height:65pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.132%;"><tr><td style="width:1.0%;"></td><td style="width:51.147%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.472%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:25.381%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investor Contact&#58; Dave Crawford</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Avanos Medical, Inc.</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">470-448-5177</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investor.Relations&#64;Avanos.com</font></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Avanos Medical, Inc. Changes to</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Virtual Meeting Format for 2020 Annual Meeting of Stockholders</font></div><div><font><br></font></div><div style="margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Alpharetta, GA., April 16, 2020&#47;PRNewswire&#47;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">-- Avanos Medical, Inc. (NYSE&#58; AVNS) announced today that, due to the increasing public health risk posed by COVID-19 and in accordance with current governmental state of emergency orders, its 2020 Annual Meeting of Stockholders will be changed from an in-person meeting to a virtual meeting to be held solely by means of remote communication.</font></div><div style="margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The 2020 Annual Meeting of Stockholders will be held, as scheduled, on Thursday, April 30, 2020 at 9 a.m. Eastern Time. As noted in the proxy statement filed by the Company on March 16, 2020, stockholders of record as of the end of business on March 2, 2020 are entitled to participate in the 2020 Annual Meeting. Stockholders will be able to attend and vote online (for those who intend to vote in person) at www.virtualshareholdermeeting.com&#47;AVNS2020 by entering the 16-digit control number provided on their proxy card. This website also contains instructions as to how to participate in the virtual 2020 Annual Meeting.</font></div><div style="margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For those who do not intend to vote at the virtual 2020 Annual Meeting, eligible stockholders may continue to vote at www.proxyvote.com, by phone, and by mail until 11&#58;59 p.m. ET on April 29, 2020, in accordance with the instructions provided in the proxy materials.</font></div><div style="margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For further information, please refer to the Avanos&#8217; Notice of 2020 Annual Meeting of Stockholders and Proxy Statement, filed with the Securities and Exchange Commission on March 16, 2020, which can be accessed at https&#58;&#47;&#47;avanos.investorroom.com&#47;financial-informationFilings.</font></div><div style="margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">About Avanos Medical, Inc.</font></div><div style="margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Avanos Medical, Inc. (NYSE&#58; AVNS) is a medical device company focused on delivering clinically superior breakthrough solutions that will help patients get back to the things that matter. Headquartered in Alpharetta, Georgia, Avanos is committed to creating the next generation of innovative healthcare solutions which will address our most important healthcare needs, such as reducing the use of opioids while helping patients move from surgery to recovery. Avanos develops, manufactures and markets its recognized brands in more than 90 countries. For more information, visit www.avanos.com.</font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>avanoslogo1.jpg
<DESCRIPTION>AVANOS LOGO
<TEXT>
begin 644 avanoslogo1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_[@ .061O8F4 9      !_^$ AD5X:68
M $U- "H    (  (!#@ "    '0   ":<FP !    .@   $0     079A;F]S
M7VQO9V]?8FQA8VLW7U)'0E\T,#!P>   00!V &$ ;@!O ', 7P!L &\ 9P!O
M %\ 8@!L &$ 8P!K #< 7P!2 $< 0@!? #0 ,  P '  >    /_L !%$=6-K
M>0 !  0   !?  #_X06&:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \
M/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z
M:V,Y9"(_/@T*/'@Z>&UP;65T82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@
M>#IX;7!T:STB061O8F4@6$U0($-O<F4@-2XV+6,Q-# @-SDN,38P-#4Q+" R
M,#$W+S U+S V+3 Q.C X.C(Q(" @(" @(" B/@T*"3QR9&8Z4D1&('AM;&YS
M.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X
M+6YS(R(^#0H)"3QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS
M.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(B!X;6QN
M<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E
M<V]U<F-E4F5F(R(@>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O(B!X;7!-33I/<FEG:6YA;$1O8W5M96YT240](GAM<"YD:60Z,V$V
M,S$V-F0M.#<P92TT.6,S+3@Y-#(M9#=D9&1C839D9F1A(B!X;7!-33I$;V-U
M;65N=$E$/2)X;7 N9&ED.CA%0S@S1#<T-3@V0S$Q13@X13DV.3 Q.34X-D4U
M0D,Q(B!X;7!-33I);G-T86YC94E$/2)X;7 N:6ED.CA%0S@S1#<S-3@V0S$Q
M13@X13DV.3 Q.34X-D4U0D,Q(B!X;7 Z0W)E871O<E1O;VP](D%D;V)E(%!H
M;W1O<VAO<"!#0R H36%C:6YT;W-H*2(^#0H)"0D\>&UP34TZ1&5R:79E9$9R
M;VT@<W12968Z:6YS=&%N8V5)1#TB>&UP+FEI9#HS838S,38V9"TX-S!E+30Y
M8S,M.#DT,BUD-V1D9&-A-F1F9&$B('-T4F5F.F1O8W5M96YT240](GAM<"YD
M:60Z,V$V,S$V-F0M.#<P92TT.6,S+3@Y-#(M9#=D9&1C839D9F1A(B\^#0H)
M"3PO<F1F.D1E<V-R:7!T:6]N/@T*"0D\<F1F.D1E<V-R:7!T:6]N('AM;&YS
M.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(^/&1C.G1I
M=&QE/CQR9&8Z06QT('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY
M.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^/')D9CIL:2!X;6PZ;&%N9STB>"UD
M969A=6QT(CY!=F%N;W-?;&]G;U]B;&%C:S=?4D="7S0P,'!X/"]R9&8Z;&D^
M/"]R9&8Z06QT/@T*"0D)/"]D8SIT:71L93X\+W)D9CI$97-C<FEP=&EO;CX\
M<F1F.D1E<V-R:7!T:6]N('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O
M96QE;65N=',O,2XQ+R(^/&1C.F1E<V-R:7!T:6]N/CQR9&8Z06QT('AM;&YS
M.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X
M+6YS(R(^/')D9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT(CY!=F%N;W-?;&]G
M;U]B;&%C:S=?4D="7S0P,'!X/"]R9&8Z;&D^/"]R9&8Z06QT/@T*"0D)/"]D
M8SID97-C<FEP=&EO;CX\+W)D9CI$97-C<FEP=&EO;CX\+W)D9CI21$8^#0H\
M+W@Z>&UP;65T83X-"CP_>'!A8VME="!E;F0])W<G/S[_VP!#  $! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(! 0$! 0(" @(" @(" @(" @," @(# P,# P,%!04%
M!04%!04%!04%!07_VP!# 0$! 0(! @," @,$! ,$! 4%!04%!04%!04%!04%
M!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!07_P  1" !! 9 #
M 1$  A$! Q$!_\0 'P   @(" P$! 0            H)"P<( P0%!@(!_\0
M6!    8! P(# P0)#0L- 0   0(#! 4&!P 1"!()(1,*,4$442(5%S)"M-26
M5W=X.6%QL7*2LB,S);75%EA2<[,D='6V-Q@X&H'!8H)#4\/C-(0UAD@9_\0
M&0$  P$! 0                ,$ @$%_\0 )!$  @,  @(# 0$! 0$
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MQGJQ9H9?X:5A)ABAU).$%-AZ#IF\0';6;^$S5/+17>?_ -;>Y5_;/SE^%/\
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M)$U#@R]KIP- "O\ ZGOBP.0^-.,^4<!&F<6' EK-5[:X;IJ*+#CC(YTDBJ*
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M RK&2<;-1S"8AY!C+1,HS;2$9*1CM-_'2+!X0%$5T%TC'26353,!B'(80$!
M0';5 D[V@"OX]25RO/FSFLQP/!2BKFD\8*V2MN6J2RGP*N3+@1"0FEN@1\LQ
MV[8&30Q@#P,D<N_MU%O:7'T595A21F]LGBTXYB\WL"X259KNJJ_MS>U9&41
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MS5JA>DF'4=1$IA\T6,H4IG#%0WM+U)B(J)*;6]^]6R;KTLBOEU"5%B[Z<_\
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M9OQ:U<+F.(LW!D8ZR-$2B7I(5)86#DI0-N(J*FV\!'5/KVY0C:OR.$ZJ$!H
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MA1N0 (,VF$^:CJ:QX8H?GGBGR0XP3RU<S]A;(6+)!)Q\*DO:*\LW@Y%7;?\
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E\# _Y\;?X74M.2E\%F'@G_5/2?\ ,;#_  1->@B-\F7-=.'_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
